Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gengwei Huo
Observed names:
Geng-Wei Huo,
Geng-wei Huo,
Huo, Gengwei,
霍庚崴
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Jining First People's Hospital,
Tianjin Medical University
ORCID:
0000-0003-3781-3323
Observed ORCID:
0000-0003-3781-3323
OpenAlex ID:
A5081625307
A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors
2021
·
Gengwei Huo
, Yali Wang
, et al.
·
Frontiers in Oncology
·
39
PDF
Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
2022
·
Qi Cai
, Geng-wei Huo
, et al.
·
Human Vaccines & Immunotherapeutics
·
36
Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
2023
·
Jinfang Cui
, Yuchao He
, et al.
·
International Journal of Biological Sciences
·
35
PDF
Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis
2023
·
Gengwei Huo
, Wenjie Liu
, et al.
·
BMC Cancer
·
31
PDF
Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
2023
·
Wenjie Liu
, Gengwei Huo
, et al.
·
BMC Cancer
·
28
PDF
Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
2020
·
Qi Zhang
, Geng-wei Huo
, et al.
·
Open Medicine
·
22
PDF
Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features
2022
·
Gengwei Huo
, Wenjie Liu
, et al.
·
Frontiers in Immunology
·
20
PDF
TWF1 induces autophagy and accelerates malignant phenotype in lung adenocarcinoma via inhibiting the cAMP signaling pathway
2023
·
Yu Wang
, Ran Zuo
, et al.
·
The FASEB Journal
·
15
PDF
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
2024
·
Gengwei Huo
, Ying Song
, et al.
·
Frontiers in Pharmacology
·
11
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis
2023
·
Gengwei Huo
, Wenjie Liu
, et al.
·
Immunotherapy
·
11
High incidence and reversible bradycardia events following alectinib initiation
2022
·
Dongqi Yuan
, Fuyi Zhu
, et al.
·
Thoracic Cancer
·
11
PDF
Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
2022
·
Wenjie Liu
, Gengwei Huo
, et al.
·
Frontiers in Immunology
·
10
PDF
Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
2021
·
Geng-wei Huo
, Ran Zuo
, et al.
·
Open Medicine
·
10
PDF
Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
2024
·
Gengwei Huo
, Ying Song
, et al.
·
Frontiers in Pharmacology
·
9
PDF
Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis
2023
·
Wenjie Liu
, Gengwei Huo
, et al.
·
Immunotherapy
·
9
Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
2023
·
Gengwei Huo
, Wenjie Liu
, et al.
·
Frontiers in Pharmacology
·
8
PDF
Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer
2024
·
Gengwei Huo
, Ying Song
, et al.
·
Journal of Gynecologic Oncology
·
7
PDF
First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
2023
·
Wenjie Liu
, Gengwei Huo
, et al.
·
Translational Lung Cancer Research
·
7
PDF
First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
2023
·
Wenjie Liu
, Gengwei Huo
, et al.
·
Frontiers in Pharmacology
·
5
PDF
Oncogenic role of TWF2 in human tumors: A pan-cancer analysis
2022
·
Wenjie Liu
, Gengwei Huo
, et al.
·
Open Medicine
·
5
PDF
Trastuzumab Deruxtecan and Sacituzumab Govitecan for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer: A Cost-Effectiveness Analysis
2025
·
Mengwei Zhang
, Gengwei Huo
, et al.
·
Clinical Therapeutics
·
4
Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
2024
·
Gengwei Huo
, Wenjie Liu
, et al.
·
Journal of Gynecologic Oncology
·
4
PDF
Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer
2024
·
Gengwei Huo
, Ying Song
, et al.
·
Journal of Gynecologic Oncology
·
4
PDF
The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis
2021
·
Geng-Wei Huo
, Fu-Yi Zhu
, et al.
·
Translational Cancer Research
·
4
PDF
Taletrectinib in ROS1+ non–small cell lung cancer: a cost-effectiveness analysis in the United States
2026
·
Gengwei Huo
, Xiaoyan Wang
, et al.
·
Frontiers in Pharmacology
·
2
PDF
Show more works
View as search
Works count:
40
Citation count:
358
H-index:
11
I10-index:
13
Year
Topic
Type